Vera Therapeutics (VERA) Accounts Payables (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Accounts Payables data on file, last reported at $13.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 50.17% year-over-year to $13.9 million; the trailing twelve-month figure through Mar 2026 stood at $13.9 million (up 50.17% YoY), and the FY2025 full-year result was $21.9 million, up 185.69% from the prior year.
• Accounts Payables for Q1 2026 stood at $13.9 million, down from $21.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $21.9 million in Q4 2025 and bottomed at $4.6 million in Q3 2024.
• The 5-year median for Accounts Payables is $9.3 million (2025), against an average of $10.2 million.
• The widest annual swing landed in 2022, when Accounts Payables soared 765.78%; it then plunged 64.88% in 2024.
• A 5-year view of Accounts Payables shows it stood at $12.0 million in 2022, then dropped by 7.28% to $11.1 million in 2023, then plunged by 31.06% to $7.7 million in 2024, then surged by 185.69% to $21.9 million in 2025, then tumbled by 36.48% to $13.9 million in 2026.
• The last three Accounts Payables figures came in at $13.9 million (Q1 2026), $21.9 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.

Peer Comparison